1747-53-1

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Dioxo-1,2,3,6-tetrahydro-4-pyrimidinecarboxylic acid ethyl ester is used as a synthetic intermediate for the development of various pharmaceutical compounds. Its role in the synthesis of drugs and active pharmaceutical ingredients is vital, contributing to the creation of novel treatments and medications.
Used in Research and Development Applications:
In the realm of scientific research, 2,6-Dioxo-1,2,3,6-tetrahydro-4-pyrimidinecarboxylic acid ethyl ester is utilized for research and development purposes. It aids chemists and pharmaceutical researchers in exploring new chemical pathways and understanding the properties of related compounds, which can lead to advancements in drug discovery and medicinal chemistry.
Safety Considerations:
It is important to handle 2,6-Dioxo-1,2,3,6-tetrahydro-4-pyrimidinecarboxylic acid ethyl ester with care due to its potential harmful effects if ingested, inhaled, or absorbed through the skin. Proper safety measures should be implemented during its use to minimize health risks.

Upstream product

• 64-17-5 ethanol 
• 65-86-1 orotic acid 
• 75500-01-5 ethyl N₁,N₃-dibenzyl orotate 
• 7647-01-0 hydrogenchloride 
• 64-19-7 acetic acid 
• 57-13-6 urea 
• 108-56-5 diethyl oxaloacetate 
• 75-03-6 ethyl iodide 
• 6314-14-3 2-(methylthio)-6-oxo-1,6-dihydropyrimidine-4-carboxylic acid 

Downstream Products

• 75500-11-7 Ethyl N₁,N₃-Dibenzyl-5,6-dihydro-orotate 
• 26409-12-1 Orotic acid hydrazide 
• 18127-43-0 ethyl 2,6-dichloropyrimidine-4-carboxylate 

Relevant academic research and scientific papers

3-METHYL-2- ( (2S) -2- (4- (3-METHYL-L, 2, 4-0XADIAZ0L-5-YL) PHENYL) MORPHOLINO) -6- (PYRIMIDIN-4-YL) PYRIMIDIN-4 (3H) -ONE AS TAU PROTEIN KINASE INHIBITOR

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g.

6-PYRIMIDINYL-PYRIMID-2-ONE DERIVATIVE

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g.

INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF

The present invention relates to a production method of an optically active morpholine compound represented by the formula 10, which includes the following steps: wherein each symbol is as defined in the specification. The present invention also relates t

REMOVAL OF N-BENZYL- AND N-BENZYLOXYMETHYL SUBSTITUENTS FROM SUBSTITUTED URACILS WITH BORON TRIBROMIDE

N1,N3-Dibenzyl uracil derivatives have been successfull deblocked by using boron tribromide in refluxing xylene.Also, N1,N3-dibenzyloxy methyl uracil derivatives can be easily converted to uracils by treatment with boron tribromide in benzene in the cold and subsequent boiling of the intermediate with water.